论文部分内容阅读
5月20日,在全国子宫颈癌协作组第四次工作会议上,专家透露,宫颈癌疫苗GARDASIL即将通过美国食品和药品管理局(FDA)的审核,成为第一个在预防宫颈癌和生殖器病变方面具有突出功效的肿瘤疫苗。目前,在提请FDA批准的同时,疫苗生产厂家也已向中国政府申请上市。那么,这一新疫苗的上市是否意味着宫颈癌将得到更有效的预防呢?它到底能给人们带来哪些益处呢?宫颈癌是第一个能用疫苗预防的恶性肿瘤中华妇产科学会副主任委员、北京大学妇产科学系主任魏丽惠告诉记者,由于宫颈癌是目前唯一一个明确致病原因的肿瘤,因此,疫苗的问世,标志着宫颈癌将成为第一个可以通过多种方法来预防和治疗的恶性肿瘤。据魏主任介绍,宫颈癌是女性最常见的一种恶性肿瘤,发病率居女性恶性肿瘤第二位。宫颈癌的致病原因
May 20, the fourth working meeting of the National Cervical Cancer Collaborative Group, experts revealed that cervical cancer vaccine GARDASIL will soon pass the US Food and Drug Administration (FDA) review, becoming the first in the prevention of cervical cancer and genital Tumor has a prominent efficacy of the tumor vaccine. At the same time, the vaccine manufacturer has also applied to the Chinese government for listing at the same time as the FDA has approved it. So, the listing of this new vaccine means that cervical cancer will be more effective prevention? It in the end can bring what benefits? Cervical cancer is the first vaccine to prevent malignant tumors Chinese Obstetrics and Gynecology Society Wei Lihui, deputy director of the Department of Obstetrics and Gynecology, Peking University, told reporters that as cervical cancer is the only clear cause of the tumor, therefore, the advent of vaccines, cervical cancer marks will be the first to come through a variety of ways Prevention and treatment of malignant tumors. According to Wei, director of introduction, cervical cancer is the most common type of cancer in women, the incidence of female malignant tumors ranked second. The cause of cervical cancer